Reducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig Models

HealthHORIZON-JU-RIAID: 101165643
EC Contribution
โ‚ฌ84,996
Consortium Size
32 orgs
Start Year
2024
โ–ถSummary

NHPig is an Innovative Health Initiative (IHI) project based on the public-private partnership of the European Union and Europeโ€™s health industries. Its objective is to expand, share and implement biological knowledge of mini-/micropig models with the aim to reduce non-human primates (NHPs) in non-clinical safety studies. The transnational consortium includes experts in porcine medical models, veterinary pathology, computational animal science, non-clinical science, OMICs profiling, new approach methods (NAMs), as well as bioinformatics and artificial intelligence. NHPig will i) characterise humanised minipigs, micropigs and tailored disease models, including systematic biobanking, multi-OMICs profiling, and state-of-the-art imaging modalities; ii) develop, validate and implement biosensors, medical devices, and โ€˜intelligentโ€™ animal housing for automated data collection and analysis in minipig safety studies; iii) fill significant knowledge gaps in the (patho)physiology of the porcine immune system; iv) validate known toxicity and efficacy biomarkers and discover novel biomarker candidates for non-clinical safety assessment; v) overcome the shortage of laboratory tools and reagents, such as validated antibodies; vi) gain experience in using mini-/micropigs for safety testing of biologicals and new therapeutic modalities; vii) Investigate in vitro to in vivo extrapolation of liver and kidney toxicity in pigs and NHP/humans to provide a comparative link to human new approach methodologies (NAMs); and viii) provide a publicly available database and IT platform for compiling, integrating and analysing existing data in NHPs/humans with data in mini-/micropig models (existing data and data generated within the NHPig programme). The establishment of a regulatory advisory board and an ethics- and animal welfare advisory board will expedite regulatory interactions and ensure compliance with the 3R principles. NHPig will generate the scientific basis for de-selection of NHPs in non-clinical safety assessment, which is an ethical requirement and also imperative according to EU legislation.

Consortium (32)

๐Ÿ‡ฉ๐Ÿ‡ช LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENDE
coordinator
AARHUS UNIVERSITET
partner
๐Ÿ‡ฎ๐Ÿ‡น AVANTEA SRLIT
partner
๐Ÿ‡ฉ๐Ÿ‡ช BAYER AKTIENGESELLSCHAFTDE
partner
๐Ÿ‡ญ๐Ÿ‡บ BIOTALENTUM TUDASFEJLESZTO KFTHU
partner
๐Ÿ‡ฉ๐Ÿ‡ช BOEHRINGER INGELHEIM INTERNATIONALGMBHDE
partner
๐Ÿ‡ฉ๐Ÿ‡ช BOEHRINGER INGELHEIM PHARMA GMBH &CO KGDE
partner
๐Ÿ‡บ๐Ÿ‡ธ BREAKTHROUGH T1DUS
partner
๐Ÿ‡ซ๐Ÿ‡ท CHARLES RIVER LABORATORIES FRANCE SAFETY ASSESSMENTFR
partner
๐Ÿ‡จ๐Ÿ‡ญ EIDGENOESSISCHES DEPARTEMENT DES INNERNCH
partner
๐Ÿ‡ฉ๐Ÿ‡ฐ ELLEGAARD GOTTINGEN MINIPIGS ASDK
partner
๐Ÿ‡ซ๐Ÿ‡ท ETISENSEFR
partner
๐Ÿ‡จ๐Ÿ‡ญ F. HOFFMANN-LA ROCHE AGCH
partner
๐Ÿ‡ฌ๐Ÿ‡ง GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITEDGB
partner
๐Ÿ‡ฉ๐Ÿ‡ฐ H. LUNDBECK ASDK
partner
๐Ÿ‡ฎ๐Ÿ‡น Istituto di Ricerche Biomediche Antoine Marxer RBM S.p.A.IT
partner
๐Ÿ‡ธ๐Ÿ‡ช KAROLINSKA INSTITUTETSE
partner
๐Ÿ‡ง๐Ÿ‡ช KATHOLIEKE UNIVERSITEIT LEUVENBE
partner
๐Ÿ‡ฌ๐Ÿ‡ง LABCORP EARLY DEVELOPMENT LABORATORIES LIMITEDGB
partner
๐Ÿ‡ญ๐Ÿ‡บ Mediso Orvosi Berendezes Fejleszto es Szerviz Kft.HU
partner
๐Ÿ‡ฉ๐Ÿ‡ช MERCK HEALTHCARE KGAADE
partner
๐Ÿ‡ฉ๐Ÿ‡ช MERCK KOMMANDITGESELLSCHAFT AUF AKTIENDE
partner
๐Ÿ‡จ๐Ÿ‡ญ NOVARTIS PHARMA AGCH
partner
๐Ÿ‡ฉ๐Ÿ‡ฐ NOVO NORDISK A/SDK
partner
๐Ÿ‡บ๐Ÿ‡ธ Sanofi US Services Inc.US
partner
๐Ÿ‡ฉ๐Ÿ‡ช SANOFI-AVENTIS DEUTSCHLAND GMBHDE
partner
๐Ÿ‡ซ๐Ÿ‡ท SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENTFR
partner
๐Ÿ‡ฉ๐Ÿ‡ช TECHNISCHE UNIVERSITAET MUENCHENDE
partner
๐Ÿ‡ง๐Ÿ‡ช UNIVERSITEIT ANTWERPENBE
partner
๐Ÿ‡จ๐Ÿ‡ฟ USTAV ZIVOCISNE FYZIOLOGIE A GENETIKY AV CR V.V.I.CZ
partner
๐Ÿ‡บ๐Ÿ‡ธ VERISIM LIFE INCUS
partner
๐Ÿ‡ฆ๐Ÿ‡น VETERINAERMEDIZINISCHE UNIVERSITAET WIENAT
partner